173) rticular, analysis of a tamoxifen-treated patient cohort indicates that Lnc-DC expre |
174) The external validation patient cohort was identified from the eIC |
175) d be explored as a therapeutic agent in a patient cohort with CRC. |
176) h findings require validation in a larger patient cohort. |
177) There are a number of patient factors and systemic changes that |
178) ed with usual care, and whether study and patient factors moderate treatment effects |
179) ion of treatment, cost of treatment), and patient-related factors (e.g., beliefs, at |
180) Objective: To identify patient-related factors and characteristic |
181) o epilepsy surgery, originating from both patient/family-related factors and physici |
182) Its annual economic burden per patient in developed countries has been cl |
183) e the experience of a medically qualified patient in having disc prolapse at three c |
184) nd often must relate pragmatically to the patient in order to solve problems and do |
185) (AEs) were mild, with the exception of 1 patient in the renal impairment study who |
186) of data to personalize care to the right patient, in the right amount, at the right |
187) their personal mobile device when seeking patient management advice from other teams |
188) d 29% smartphone photography when seeking patient management advice. |
189) inding may have important implication for patient management. |
190) cancer can facilitate subsequent clinical patient management. |
191) l cases as well as group comparisons, and patient-tailored management. |
192) Patient navigation interventions, which ar |
193) Patient navigation is a model of care that |
194) onducted a scoping review to identify all patient navigation interventions in LICs. |
195) aper is to synthesize what is known about patient navigation interventions to facili |
196) acilitate or impede the implementation of patient navigation programs (PNPs). |
197) tinum compounds is a major determinant of patient survival in high-grade serous ovar |
198) related genes and cutaneous melanoma (CM) patient survival remains unknown. |
199) sis, which will have invaluable impact on patient survival. |
200) polyamine metabolism and their impact on patient survival. |
201) the two drugs could ultimately compromise patient survival. |
202) es language barriers in expatriate doctor-patient communication in three state-owned |
203) arch may identify opportunities where the patient-provider communication dynamic can |
204) There has been limited research on patient-provider communication dynamics re |
205) ormation regarding disease and treatment, patient-provider communication was limited |
add keyword